A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Crystal Palace were promoted to replace Bristol City in the top flight, while on a wider note, the league is now under the ...

Crystal Palace were promoted to replace Bristol City in the top flight, while on a wider note, the league is now under the ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The company's significant announcement on March 31, detailing the successful Phase 3 trial results of the ROSELLA study, likely provided a strong boost to investor confidence, as it highlighted a ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal, showing promise for relacorilant in treating platinum-resistant ovarian cancer. The ROSELLA trial ...

Corcept Therapeutics (CORT) announced that Rosella, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary ...

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 Corcept Therapeutics Incorporated (NASDAQ: CORT), a ...

In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in risk of disease progression compared to patients treated with nab ...

The data will be presented in a late-breaking oral presentation on Monday, June 2, 2025. The ROSELLA trial is being conducted in collaboration with The GOG Foundation, Inc. (GOG-F), the European ...